Page 24 - Delaware Medical Journal - June 2016
P. 24
REFERENCES
1. Steiner RD, Pepin MG, Byers PH. Osteogenesis Imperfecta. In: Pagon RA, Bird TD, Dolan CR, Stephens K, eds. Gene Reviews. Seattle, Wa: University of Washington; 1993.
2. Peltier LF. The classic: congenital osteomalacia. Olaus Jacob Ekman. Clin Orthop Relat Res. 1981;3-5.
3. Looser E. Zur Kenntnis der Osteogenesis Imperfecta Congenita et Tarda (sogenannte idiopathischeOsteopsatyrosis). Mittlg Grenzgebiete Med Chir. 1906;15:161-207.
4. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16:101–116
5. Rauch F, Glorieux FH. Osteogenesis imperfecta. The Lancet. 2004;363:1377-1385.
6. Glorieux FH, Rauch F, Plotkin H, et al. Type V osteogenesis imperfecta: a new form
of brittle bone disease. J Bone Miner Res. 2000;15:1650–1658.
7. Hoyer-Kuhn H, Netzer C, Semler O. Osteogenesis imperfecta: Pathophysiology and treatment. Wiener Medizinische Wochenschrift. 2015;165:278-284.
8. Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ, Travers R. Osteogenesis imperfect type VI: a form of brittle bone disease with a mineralization defect.
J Bone Miner Res. 2002;17:30-38.
9. Rauch F, Glorieux FH. Osteogenesis imperfecta.
The Lancet. 2004;363:1377-1385.
10. Van Dijk FS, Sillence DO. Osteogenesis imperfecta: Clinical diagnosis, nomenclature and severity assessment. Am J Med Genet Part A. 2014; 164(6):1470-1481.
11. Dalgleish R. The human type I collagen mutation database. Nucleic Acids Res. 1997;25:181-187.
12. Forlino A, Marini JC. Osteogenesis imperfecta: prospects for molecular therapeutics. Mol Genet Metab. 2000;71:225–32.
13. Marini JC, Forlino A, Cabral WA, et al. Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans.
Hum Mutat. 2007;28:209-221.
14. Viora E, Sciarrone A, Bastonero S, et al.
Increased nuchal translucency
in the first trimester as a sign of osteogenesis imperfecta.
Am J Med Genet. 2002;109:336-337.
15. Morgan JA, Marcus PS. Prenatal diagnosis and management of intrauterine fracture. Obstet Gynecol Surv. 2010;65:249-259.
16. Vimercati A, Panzarino M, Totaro I,
Chincoli A, Selvaggi L. Increased nuchal translucency and short femur length as possible early signs of osteogenesis imperfecta type III. J Prenat Med. 2013;7:5.
17. Van Dijk FS, Byers PH, Dalgleish R, Malfait F, Maugeri A, Rohrbach M. EMQN best practice guidelines for the laboratory diagnosis of osteogenesis imperfecta. Eur J Hum Genet. 2012;20:11-19.
18. Greeley CS, Donaruma-Kwoh M, Vettimattam M, Lobo C, Williard C, Mazur L. Fractures at Diagnosis in Infants and Children With Osteogenesis Imperfecta. J Pediatr Ortho. 2013;33:32-36.
19. Chapman S, Hall CM. Non-accidental injury or brittle bones.
Pediatr Radiol. 1997;27:106-110.
20. Knight DJ, Bennet GC. Nonaccidental injury in osteogenesis imperfecta: a case report. J Pediatr Ortho. 1990;10:542-544.
21. Bulloch B, Schubert CJ, Brophy PD, Johnson N, Reed MH, Shapiro RA. Cause and clinical characteristics of rib fractures in infants. Pediatrics. 2000;105:e48
22. Metz JB, Schwartz KW, Feldman DM, et al. Non-cutaneous conditions clinicians might mistake for abuse.
Arch Dis Child. 2014;99:817-823.
23. Plotkin H, Rauch F, Bishop NJ, et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab. 2000;85:1846-1850.
24. Moore MS, Minch CM, Kruse RW, Harcke HT, Jacobsen L, Taylor A. The role of dual energy x-ray absorptiometry in aiding
the diagnosis of pediatric osteogenesis imperfecta. Am J Orthop. 1998;27:797-801.
25. Fratzl-Zelman N, Misof B, Klaushofer
K, Roschger P. Bone mass and mineralization in osteogenesis imperfecta. Wiener Medizinische Wochenschrift. 2015;165:271-277.
26. Burnei G, Vlad C, Georgescu I, et al. Osteogenesis imperfecta: diagnosis and treatment. J Am Acad Orthop Surg. 2008;16:356-366.
27. Pedersen U, Bramsen T. Central corneal thickness in osteogenesis imperfecta and otosclerosis. ORL. 1984;46:38-41.
28. Aase JM. Diagnostic Dysmorphology. Springer; 1990.
29. Barron MJ, McDonnell ST, Mackie I,
Dixon MJ. Hereditary dentine disorders: dentinogenesis imperfecta and dentine dysplasia. Orphanet J Rare Dis. 2008;3:31.
30. Kuurila K, Kaitila I, Johansson R, Grénman R. Hearing loss in Finnish adults with osteogenesis imperfecta: a nationwide survey. Ann Otol Rhinol Laryngol. 2002;111:939-946.
31. Monti E, Mottes M, Fraschini P, et al. Current and emerging treatments for the management of osteogenesis imperfecta. Ther Clin Risk Manag. 2010;6:367-381.
32. Aarabi M, Rauch F, Hamdy RC, Fassier F. High prevalence of coxa vara in patients with severe osteogenesis imperfecta.
J Pediatr Orthop. 2006;26:24-28.
33. Widmann RF, Bitan FD, Laplaza FJ, Burke SW, DiMaio MF, Schneider R. Spinal deformity, pulmonary compromise, and quality of life in osteogenesis imperfecta. Spine. 1999;24:1673-1678.
34. Lubicky JP. The Spine in Osteogenesis Imperfecta. In: Weinstein SL, ed. The Pediatric Spine: Principles and Practice. New York, NY: Raven Press Ltd; 1994:943-58.
35. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
N Engl J Med. 1998;339:947-952.
36. Philippi CA, Remmington T, Steiner RD. Bisphosphonate therapy for osteogenesis imperfecta. The Cochrane Library. 2008.
37. Kusumi K, Ayoob R, Bowden S, Ingraham S, Mahan J. Beneficial effects of intravenous pamidronate treatment in children with osteogenesis imperfecta under 24 months of age. J Bone Miner Metab. 2014;560-568.
38. Shaw NJ, Bishop NJ. Bisphosphonate treatment of bone disease.
Arch Dis Child. 2005;90:494-499.
39. Muderis M, Azzopardi t, Cundy P. Zebra lines of pamidronate therapy in children.
J Bone Joint Surg Am, 2007;89:1511-1516.
40. DiMeglio LA, Peacock M. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.
J Bone Miner Res. 2006;21:132-140.
41. Bishop N, Adami S, Ahmed SF, et al. Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial.
Lancet. 2013;382:1424-1432.
42. Otaify G, Aglan M, Ibrahim M, Elnashar
M, Banna R, Temtamy S. Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study.
Osteoporosis Int. 2016;27;81-92.
43. Dwan K, Phillipi CA, Steiner RD, Basel D. “Bisphosphonate therapy for osteogenesis imperfecta.” Cochrane Database of Systematic Reviews. 2014;7.
44. Munns CF, Rauch F, Zeitlin L, Fassier F, Glorieux FH: Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res. 2004;19:1779-1786.
45. Van Poznak C, Ward BB. Osteonecrosis of the jaw. Curr Opin Orthop. 2006;17:462-468.
184
Del Med J | June 2016 | Vol. 88 | No. 6
